MacroGenics receives $24.5M milestone from Sanofi after FDA approval
MacroGenics will receive a $24.5 million regulatory milestone payment from Sanofi following the FDA's accelerated approval of TZIELD for children aged eight to 17 with stage 3 type 1 diabetes. The company remains eligible for up to $305 million in additional milestones and royalties on global net sales above a specified threshold.
*this image is generated using AI for illustrative purposes only.
MacroGenics, Inc. will receive a $24.5 million regulatory milestone payment from Sanofi following the U.S. Food and Drug Administration’s (FDA) accelerated approval of TZIELD® (teplizumab-mzwv). The approval expands the indication to delay the decline in endogenous insulin production in children aged eight to 17 years recently diagnosed with stage 3 type 1 diabetes (T1D). This development enhances the therapeutic potential of TZIELD as a disease-modifying therapy for type 1 diabetes.
Under the terms of the agreement between MacroGenics and Sanofi, the recent FDA approval triggered the $24.5 million regulatory milestone payable to MacroGenics. The payment reflects the expanded regulatory clearance for the product in a younger patient demographic.
Future Financial Obligations
MacroGenics remains eligible to receive up to $305 million in additional milestone payments related to the TZIELD program. Furthermore, the company retains the right to receive a single-digit royalty on global net sales above a specified annual threshold.
| Financial Detail | Amount |
|---|---|
| Regulatory Milestone Received | $24.5 million |
| Potential Additional Milestones | Up to $305 million |
| Royalty Basis | Single-digit on global net sales above threshold |
What are the specific milestones that MacroGenics must achieve to unlock the remaining $305 million in potential payments?
How will Sanofi's commercial strategy impact the adoption rate of TZIELD in the newly approved pediatric demographic?
What are the projected timelines for reaching the global net sales threshold required to trigger royalty payments?
16
Access 50+ Readymade Screeners 
Use 200+ Custom Filters 
Get Full Market Insights 
